1. Home
  2. TRN vs ACAD Comparison

TRN vs ACAD Comparison

Compare TRN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinity Industries Inc.

TRN

Trinity Industries Inc.

HOLD

Current Price

$34.08

Market Cap

2.6B

Sector

Industrials

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.25

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRN
ACAD
Founded
1933
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.8B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
TRN
ACAD
Price
$34.08
$25.25
Analyst Decision
Hold
Buy
Analyst Count
1
22
Target Price
$34.00
$30.55
AVG Volume (30 Days)
706.6K
1.6M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
4.03%
N/A
EPS Growth
85.98
69.12
EPS
0.30
0.02
Revenue
$2,156,900,000.00
$726,437,000.00
Revenue This Year
$1.91
$18.80
Revenue Next Year
$15.61
$11.70
P/E Ratio
$115.27
$1,265.50
Revenue Growth
N/A
40.45
52 Week Low
$22.38
$19.69
52 Week High
$37.36
$28.35

Technical Indicators

Market Signals
Indicator
TRN
ACAD
Relative Strength Index (RSI) 48.20 74.58
Support Level $31.12 $20.39
Resistance Level $35.43 $27.91
Average True Range (ATR) 1.01 0.85
MACD -0.03 0.43
Stochastic Oscillator 33.47 67.54

Price Performance

Historical Comparison
TRN
ACAD

About TRN Trinity Industries Inc.

Trinity Industries Inc sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in two main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: